Odiparcil

Drug Profile

Odiparcil

Alternative Names: 424323; SB 424323

Latest Information Update: 22 Jan 2008

Price : $50

At a glance

  • Originator Fournier Pharma
  • Class Antithrombotics; Glycosides; Small molecules
  • Mechanism of Action Glycosaminoglycan stimulants; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis

Most Recent Events

  • 03 Aug 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the adverse events and Thromboses therapeutic trials sections
  • 27 Mar 2007 GlaxoSmithKline appears to have discontinued development of odiparcil; Solvay is now responsible for further development
  • 28 Jul 2005 Fournier-Pharma has been acquired by Solvay
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top